Global Perspectives in Gastrointestinal Malignancies in 2024

Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

July 8 and 12, 2024
Purchase Report
Howard Hochster, MD, FACP, Aptitude Health Scientific Leader

Faculty Chair

Howard S. Hochster, MD

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

Faculty Members

Dirk Arnold, MD, PhD
University of Hamburg, Germany

Gerald Prager, MD
University of Vienna, Austria

Julien Taieb, MD, PhD
University of Paris, France

Efrat Dotan, MD
Fox Chase Cancer Center, Philadelphia, PA, USA

Tanios Bekaii-Saab, MD, FACP
Mayo Clinic Cancer Center, Phoenix, AZ, USA

Kristen Ciombor, MD, MSCI
Vanderbilt University Medical Center, Nashville, TN, USA

Nataliya Uboha, MD, PhD
University of Wisconsin, Madison, WI, USA

Sample Report

Start discovering the insights

View Report

REPORT TOPICS INCLUDE

  • Metastatic Colorectal Cancer – Chemotherapy, Targeted Therapies, and Biomarker-Driven Treatments
  • Colorectal Cancer – Immunotherapy
  • Rectal Cancer
  • Gastroesophageal Junction (GEJ) and Gastric Cancer
  • Hepatocellular Carcinoma (HCC)
  • Pancreatic Cancer
  • Biliary Tract Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.